ONWARD1

Advertisement

cGxPJobs Banner

Alumis Advances Envudeucitinib With 54% PASI 100 Response

SOUTH SAN FRANCISCO, California, August 10, 2026 Alumis Inc. announced topline long-term results from the ongoing Phase 3 ONWARD3...

By cGxPwire Editor
August 12, 2026

Read More

Advertisement

cGxPJobs

Directory